CordenPharma is a contract development and manufacturing organization (CDMO) serving pharmaceutical and biotechnology companies. The company develops and manufactures active pharmaceutical ingredients (APIs), excipients, and finished drug products under GMP, supporting projects from early clinical phases through commercial supply.
Its expertise spans complex modalities and challenging chemistries, including peptides, oligonucleotides, specialized lipids (such as those used in lipid nanoparticle formulations), and highly potent and oncology APIs, alongside conventional small-molecule APIs. Capabilities include process and analytical development, scale-up and tech transfer, sterile and non-sterile drug product manufacturing (e.g., injectables and oral solid dosage forms), and integrated quality and regulatory support. CordenPharma operates a network of specialized manufacturing sites in Europe and North America.
chemXplore tracks 3 projects involving CordenPharma.
CordenPharma's role on them: Owner.
The consortium will produce 80 million mRNA vaccine doses annually if needed, following a successful expansion and qualification phase, ensuring pandemic readiness for at least five years.
